Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer

NCT01812668 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Adenocarcinoma of the Prostate
Hormone-resistant Prostate Cancer
Recurrent Prostate Cancer
Stage IV Prostate Cancer

Interventions

DRUG: cabozantinib-s-malate
RADIATION: fluorine F 18 d-FMAU
PROCEDURE: positron emission tomography
OTHER: pharmacological study
OTHER: laboratory biomarker analysis

Sponsor

Barbara Ann Karmanos Cancer Institute